<産業資料/調査レポートの題名> 2022年4月19日

眼科治療の世界市場2020-2024


◆英文タイトル:Global Ophthalmology Therapeutics Market 2020-2024

01: EXECUTIVE SUMMARY
02: SCOPE OF THE REPORT
1. 2.1 Preface
2. 2.2 Currency conversion rates for US$
03: MARKET LANDSCAPE
3. Market ecosystem
4. Parent market
5. Market characteristics
6. Value chain analysis
7. Market segmentation analysis
04: MARKET SIZING
8. Market definition
9. Market sizing 2019
10. Market size and forecast 2019-2024
11. Market outlook
05: FIVE FORCES ANALYSIS
12. Bargaining power of buyers
13. Bargaining power of suppliers
14. Threat of new entrants
15. Threat of substitutes
16. Threat of rivalry
17. Market condition
06: MARKET SEGMENTATION BY PRODUCT
18. Market segmentation by product
19. Comparison by product
20. Retinal disorder therapeutics – Market size and forecast 2019-2024
21. Glaucoma therapeutics – Market size and forecast 2019-2024
22. Dry eye disease therapeutics – Market size and forecast 2019-2024
23. Eye infections and inflammation therapeutics –
24. Market size and forecast 2019-2024
25. Other therapeutics – Market size and forecast 2019-2024
26. Market opportunity by product
07: CUSTOMER LANDSCAPE
08: GEOGRAPHIC LANDSCAPE
27. Geographic segmentation
28. Geographic comparison
29. North America – Market size and forecast 2019-2024
30. Europe – Market size and forecast 2019-2024
31. Asia – Market size and forecast 2019-2024
32. ROW – Market size and forecast 2019-2024
33. Key leading countries
34. Market opportunity
09: DECISION FRAMEWORK
10: DRIVERS AND CHALLENGES
35. Market drivers
36. Market challenges
11: MARKET TRENDS
37. Development of novel drug delivery systems
38. Increase in strategic alliances
39. Increasing research on gene therapy products
12: VENDOR LANDSCAPE
40. Overview
41. Landscape disruption
42. Competitive scenario
13: VENDOR ANALYSIS
43. Vendors covered
44. Vendor classification
45. Market positioning of vendors
46. AbbVie Inc.
47. Aerie Pharmaceuticals Inc.
48. Bayer AG
49. F. Hoffmann-La Roche Ltd.
50. Novartis AG
51. Otsuka Holdings Co. Ltd.
52. Pfizer Inc.
53. Regeneron Pharmaceuticals Inc.
54. Santen Pharmaceutical Co. Ltd.
55. Teva Pharmaceutical Industries Ltd.
14: APPENDIX
56. Research methodology
57. List of abbreviations
58. Definition of market positioning of vendors
15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Product overview
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Product – Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Retinal disorder therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Retinal disorder therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 22: Glaucoma therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Glaucoma therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 24: Dry eye disease therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Dry eye disease therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 26: Eye infections and inflammation therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 27: Eye infections and inflammation therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 28: Other therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 29: Other therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2019-2024 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 35: North America – Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in North America
Exhibit 37: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in Europe
Exhibit 40: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 41: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 42: Top 3 countries in Asia
Exhibit 43: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 44: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 45: Top 3 countries in ROW
Exhibit 46: Key leading countries
Exhibit 47: Market opportunity
Exhibit 48: Late-stage pipeline drugs
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie Inc. – Vendor overview
Exhibit 56: AbbVie Inc. – Business segments
Exhibit 57: AbbVie Inc. – Organizational developments
Exhibit 58: AbbVie Inc. – Geographic focus
Exhibit 59: AbbVie Inc. – Key offerings
Exhibit 60: AbbVie Inc. – Key customers
Exhibit 61: Aerie Pharmaceuticals Inc. – Vendor overview
Exhibit 62: Aerie Pharmaceuticals Inc. – Business segments
Exhibit 63: Aerie Pharmaceuticals Inc. – Organizational developments
Exhibit 64: Aerie Pharmaceuticals Inc. – Key offerings
Exhibit 65: Aerie Pharmaceuticals Inc. – Key customers
Exhibit 66: Bayer AG – Vendor overview
Exhibit 67: Bayer AG – Business segments
Exhibit 68: Bayer AG – Organizational developments
Exhibit 69: Bayer AG – Geographic focus
Exhibit 70: Bayer AG – Segment focus
Exhibit 71: Bayer AG – Key offerings
Exhibit 72: Bayer AG – Key customers
Exhibit 73: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 74: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 75: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 76: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 77: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 78: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 79: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 80: Novartis AG – Vendor overview
Exhibit 81: Novartis AG – Business segments
Exhibit 82: Novartis AG – Organizational developments
Exhibit 83: Novartis AG – Geographic focus
Exhibit 84: Novartis AG – Segment focus
Exhibit 85: Novartis AG – Key offerings
Exhibit 86: Novartis AG – Key customers
Exhibit 87: Otsuka Holdings Co. Ltd. – Vendor overview
Exhibit 88: Otsuka Holdings Co. Ltd. – Business segments
Exhibit 89: Otsuka Holdings Co. Ltd. – Organizational developments
Exhibit 90: Otsuka Holdings Co. Ltd. – Geographic focus
Exhibit 91: Otsuka Holdings Co. Ltd. – Segment focus
Exhibit 92: Otsuka Holdings Co. Ltd. – Key offerings
Exhibit 93: Otsuka Holdings Co. Ltd. – Key customers
Exhibit 94: Pfizer Inc. – Vendor overview
Exhibit 95: Pfizer Inc. – Business segments
Exhibit 96: Pfizer Inc. – Organizational developments
Exhibit 97: Pfizer Inc. – Geographic focus
Exhibit 98: Pfizer Inc. – Segment focus
Exhibit 99: Pfizer Inc. – Key offerings
Exhibit 100: Pfizer Inc. – Key customers
Exhibit 101: Regeneron Pharmaceuticals Inc. – Vendor overview
Exhibit 102: Regeneron Pharmaceuticals Inc. – Business segments
Exhibit 103: Regeneron Pharmaceuticals Inc. – Organizational developments
Exhibit 104: Regeneron Pharmaceuticals Inc. – Key offerings
Exhibit 105: Regeneron Pharmaceuticals Inc. – Key customers
Exhibit 106: Santen Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 107: Santen Pharmaceutical Co. Ltd. – Business segments
Exhibit 108: Santen Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 109: Santen Pharmaceutical Co. Ltd. – Segment focus
Exhibit 110: Santen Pharmaceutical Co. Ltd. – Key offerings
Exhibit 111: Santen Pharmaceutical Co. Ltd. – Key customers
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 114: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 115: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 116: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 117: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 118: Validation techniques employed for market sizing
Exhibit 119: Definition of market positioning of vendors



LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark